Edwards Lifesciences Beats Analyst Estimates on EPS

Seth Jayson, The Motley Fool
Updated

Edwards Lifesciences (NYS: EW) reported earnings on Oct. 19. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Edwards Lifesciences missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded significantly.


Margins expanded across the board.

Revenue details
 Edwards Lifesciences booked revenue of $448.0 million. The 20 analysts polled by S&P Capital IQ predicted revenue of $476.6 million on the same basis. GAAP reported sales were 8.5% higher than the prior-year quarter's $412.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.58. The 22 earnings estimates compiled by S&P Capital IQ averaged $0.56 per share. GAAP EPS of $0.58 for Q3 were 35% higher than the prior-year quarter's $0.43 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 75.1%, 550 basis points better than the prior-year quarter. Operating margin was 21.1%, 660 basis points better than the prior-year quarter. Net margin was 15.4%, 290 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $500.6 million. On the bottom line, the average EPS estimate is $0.80.

Next year's average estimate for revenue is $1.89 billion. The average EPS estimate is $2.57.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 147 members out of 202 rating the stock outperform, and 55 members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Edwards Lifesciences a green thumbs-up, and 22 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Edwards Lifesciences is outperform, with an average price target of $104.37.

The article Edwards Lifesciences Beats Analyst Estimates on EPS originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement